Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/52031
Campo DC Valoridioma
dc.contributor.authorWägner, Ana M.en_US
dc.contributor.authorJorba, Oscaren_US
dc.contributor.authorBonet, Rosaen_US
dc.contributor.authorOrdóñez-Llanos, Jordien_US
dc.contributor.authorPérez, Antonioen_US
dc.date.accessioned2018-11-25T16:51:48Z-
dc.date.available2018-11-25T16:51:48Z-
dc.date.issued2003en_US
dc.identifier.issn0021-972Xen_US
dc.identifier.urihttp://hdl.handle.net/10553/52031-
dc.description.abstractTo compare the effects of atorvastatin, gemfibrozil, and their combination on the components of diabetic dyslipidemia, 44 type 2 diabetic patients with low density lipoprotein cholesterol (LDLc) levels greater than 100 mg/dl and triglyceride levels less than 400 mg/dl were included. Twelve-week treatments with atorvastatin (10–20 mg/d) and gemfibrozil (900–1200 mg/d) were given in random order in an open, cross-over study and then combined (10 mg atorvastatin and 900 mg gemfibrozil) for 12 additional wk. Triglyceride, LDLc, high density lipoprotein cholesterol (HDLc), non-HDLc, apolipoprotein B (apoB), and LDL size were measured at baseline and after each treatment. Atorvastatin was more effective (P < 0.001) in lowering LDLc, non-HDLc, and apoB and in achieving treatment goals, whereas gemfibrozil lowered triglyceride levels more effectively (P < 0.001) and increased LDL size (from 25.59 ± 0.06 to 25.69 ± 0.06 nm; P < 0.05). Combined treatment with both drugs reduced LDLc, triglyceride, non-HDLc, and apoB by 26.5%, 24.1%, 30.4%, and 21.8%, respectively; increased HDLc by 4.8% and LDL size by 0.1 nm; and was the most effective treatment in reaching the therapeutic targets, especially in patients with triglyceride levels higher than 150 mg/dl. In conclusion, statins are first choice drugs in diabetic patients with low to moderate risk LDLc, although their combination with fibrates might be the most appropriate treatment, especially when triglyceride levels are above the therapeutic goal.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Clinical Endocrinology and Metabolismen_US
dc.sourceJournal of Clinical Endocrinology and Metabolism[ISSN 0021-972X],v. 88(7), p. 3212-3217 (Julio 2003)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320502 Endocrinologíaen_US
dc.subject3209 Farmacologíaen_US
dc.subject.otherApolipoproteinen_US
dc.subject.otherHigh density lipoprotein cholesterolen_US
dc.subject.otherLow density lipoprotein cholesterolen_US
dc.subject.otherAtorvastatinen_US
dc.subject.otherGemfibrozilen_US
dc.subject.otherDiabetic dyslipidemiaen_US
dc.titleEfficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemiaen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1210/jc.2003-030153en_US
dc.identifier.scopus0038637253-
dc.contributor.authorscopusid7401456520-
dc.contributor.authorscopusid6602639970-
dc.contributor.authorscopusid6701846436-
dc.contributor.authorscopusid7005297613-
dc.contributor.authorscopusid7402509742-
dc.description.lastpage3217en_US
dc.identifier.issue7-
dc.description.firstpage3212en_US
dc.relation.volume88en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.numberofpages6en_US
dc.utils.revisionen_US
dc.date.coverdateJulio 2003en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.jcr5,873-
dc.description.jcrqQ1-
dc.description.scieSCIE-
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Diabetes y endocrinología aplicada-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-7663-9308-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameWägner, Anna Maria Claudia-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

38
actualizado el 17-nov-2024

Citas de WEB OF SCIENCETM
Citations

29
actualizado el 17-nov-2024

Visitas

38
actualizado el 09-sep-2023

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.